管线成果超预期获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件

智通财经01-14

智通财经APP获悉，今天，以 AI+机器人赋能新药与新材料研发的创新平台型企业晶泰科技(02228)宣布，其孵化企业 ReviR 溪砾科技(下称“ReviR”)的创新药管线 RTX-117 近日成功实现中美“双报双批”(IND 获批)的里程碑成果，结合多项合作的成功进展，晶泰科技将获得由 ReviR 支付的总计数千万港币的里程碑付款。ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603573916?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603573916","market":"hk","top_or_hot":-1,"title":"管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，今天，以 AI+机器人赋能新药与新材料研发的创新平台型企业晶泰科技(02228)宣布，其孵化企业 ReviR 溪砾科技(下称“ReviR”)的创新药管线 RTX-117 近日成功实现中美“双报双批”(IND 获批)的里程碑成果，结合多项合作的成功进展，晶泰科技将获得由 ReviR 支付的总计数千万港币的里程碑付款。ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392536.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 09:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1392536.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，今天，以 AI+机器人赋能新药与新材料研发的创新平台型企业晶泰科技(02228)宣布，其孵化企业 ReviR 溪砾科技(下称“ReviR”)的创新药管线 RTX-117 近日成功实现中美“双报双批”(IND 获批)的里程碑成果，结合多项合作的成功进展，晶泰科技将获得由 ReviR 支付的总计数千万港币的里程碑付款。ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392536.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1392536.html","article_id":"2603573916","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603573916","pubTimestamp":1768353831,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技有权参与该管线的销售分成及后续授权收益分成。RTX-117 为晶泰科技与 ReviR 深度合作的一系列研发管线中首个里程碑成果，其临床前数据及临床获批速度均超出双方预期。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02228":"晶泰控股","BK4585":"ETF&股票定投概念","RTX":"雷神技术公司","BK4139":"生物科技","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4566":"资本集团","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","BK4505":"高瓴资本持仓","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","RNA":"Atrium Therapeutics","BK4550":"红杉资本持仓","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4588":"碎股","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK1617":"AI医疗","BK1141":"生命科学工具和服务","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4187":"航天航空与国防"},"translate_title":"The pipeline results exceeded expectations and received tens of millions of Hong Kong dollars in milestone payments! Jingtai Technology (02228) 's new AI + RNA drug RTX-117 received clinical approval from China and the United States","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1.5,"RNA":1.5,"RTX":1.5},"content_text":"智通财经APP获悉，今天，以 AI+机器人赋能新药与新材料研发的创新平台型企业晶泰科技(02228)宣布，其孵化企业 ReviR 溪砾科技(下称“ReviR”)的创新药管线 RTX-117 近日成功实现中美“双报双批”(IND 获批)的里程碑成果，结合多项合作的成功进展，晶泰科技将获得由 ReviR 支付的总计数千万港币的里程碑付款。ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技有权参与该管线的销售分成及后续授权收益分成。CMT 由基因变异引起，具有进展性强、致残性高的特点，既是一种罕见病，也是一类最常见的遗传性周围神经病，全球患者总数超过 260 万。RTX-117 由晶泰科技基于其 AI+ 机器人药物研发平台与 ReviR 合作开发，是国内首款针对 CMT 的 1 类创新药管线，也是当前国内唯一一款从疾病相关的病理通路出发，从分子源头干预疾病进程的 CMT 药物，有望打破 CMT 长期缺乏有效治疗药物的僵局，撬动全球超 100 亿美元的潜在治疗市场。值得注意的是，RTX-117 除了适用于现有 CMT 患者群体，还具备极大的适应症拓展潜力，潜在覆盖人群预估超过 5000 万，是现有 CMT 患者数量的近 20 倍。RTX-117 的作用机制在于精准靶向 CMT 致病的关键通路，通过抑制异常激活的整合应激反应(Integrated Stress Response, ISR)，恢复 mRNA 的正常翻译，从而发挥疗效。据 ReviR 消息，临床前数据显示，RTX-117 展现出高药效强度和高水平的靶点结合能力，对 ISR 抑制效果显著，并能有效恢复模型动物的运动能力。RTX-117 为晶泰科技与 ReviR 深度合作的一系列研发管线中首个里程碑成果，其临床前数据及临床获批速度均超出双方预期。即将开展的临床研究将评估该突破性疗法的安全性和有效性，为全球数百万受 CMT 及相关疾病困扰的患者带来潜在的治疗希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603573916","isCrawlerRequest":true}

管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件

精彩评论

管线成果超预期获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件